68.57
68.57 (0%)
As of Apr 17, 2025
Dexcom Inc [DXCM]
Source:
Company Overview
Dexcom Inc is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | ( 858 ) 200-0200 |
| Industry | manufacturing |
| CEO | Kevin R. Sayer |
| Website | dexcom.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $4,033 |
| Operating Profit | $600 |
| Net Income | $576.2 |
| Net Cash | $39.8 |
Profit Ratios
| Gross Margin | $2,438.2 |
| Operating Margin | 14.9 |
| Profit as % of Revenues | 423.2% |
| Profit as % of Assets | 9% |
| Profit as % of Stockholder Equity | 27.4% |
Management Effectiveness
| Return on Equity | 27.4% |
| Return on Assets | 8.9% |
| Turnover Ratio | 63.3% |
| EBITA | $600 |
Balance Sheet and Cash Flow Measures
| Total Assets | $6,484.5 |
| Total Liabilities | $4,381.9 |
| Operating Cash Flow | $989.5 |
| Investing Cash Flow | $-207.5 |
| Financing Cash Flow | $-734.8 |
